Results

Total Results: 2,146 records

Showing results for "factor".

1. Recombinant-Factor-Viia Clinician (pdf file)
   effectivehealthcare.ahrq.gov/sites/default/files/pdf/recombinant-factor-viia_clinician.pdf
   October 01, 2010 - Vessel Conditions Off-Label Uses of rFVIIa Key Clinical Issue Off-label use of recombinant activated factor … of bleeding in patients with hemophilia A or B with inhibitors, acquired hemophilia, or congenital factor … Utilization and Clinical Data on In-Hospital, Off-Label Uses of Recombinant Factor VIIa 1 In January … information in this guide is based on Comparative Effectiveness of In-Hospital Use of Recombinant Factor

2. Comparative Effectiveness of In-Hospital Use of Recombinant Factor VIIa for Off-Label Indications vs. Usual Care | Effective Health Care (EHC) Program
   effectivehealthcare.ahrq.gov/products/recombinant-factor-viia/research/

3. Comparative Effectiveness of In-Hospital Use of Recombinant Factor VIIa for Off-Label Indications vs. Usual Care | Effective Health Care (EHC) Program
   effectivehealthcare.ahrq.gov/products/recombinant-factor-viia/

4. Effectiveness and Off-Label Use of Recombinant Factor VIIa | Effective Health Care (EHC) Program
   effectivehealthcare.ahrq.gov/products/recombinant-factor-viia/slides
   August 14, 2013 - Effectiveness and Off-Label Use of Recombinant Factor VIIa Presentation Archived August 14, 2013

5. Effective Health Care Program
   effectivehealthcare.ahrq.gov/health-topics/lupus-0
   March 07, 2012 - Antinuclear Antibody, Rheumatoid Factor, and Cyclic-Citrullinated Peptide Tests for Evaluating Musculoskeletal … Children Systematic Review Archived March 7, 2012 Antinuclear Antibody, Rheumatoid Factor

6. Layout 1 (pdf file)
   effectivehealthcare.ahrq.gov/sites/default/files/related_files/recombinant-factor-viia_executive.pdf
   May 01, 2010 - currently available to support the effectiveness and safety of using recombinant activated coagulation factor … uses in hemophilia patients who have developed antibody inhibitors that compromise the use of standard factor … Comparative Effectiveness of In-Hospital Use of Recombinant Factor VIIa for Off-Label Indications vs … rFVIIa is a form of human factor VII produced by recombinant technology. … VIII or factor IX, respectively.

7. Dental Care for People With Hemophilia: A Rapid Response Literature Review (pdf file)
   effectivehealthcare.ahrq.gov/sites/default/files/related_files/hemophilia-dental-rapid-response.pdf
   July 01, 2024 - "[ot] OR "Factor IX Deficiency"[ot] OR "Christmas Disease"[ot] OR "factor viii deficiency"[ot] OR "factor … 8' OR 'antih*emophilic factor' OR 'antih*emophilic globulin' OR 'factor viii' OR 'factor ix' OR 'factor … ix' OR 'factor xi' OR 'plasma thromboplastin component' OR 'factor 8' OR 'factor 9' OR f9 OR 'factor … factor VIII by 2%. … “Antihemophilic factor is not the only answer for all factor VIII deficiencies.”

8. Evidence-based Practice Center Systematic Review Protocol (pdf file)
   effectivehealthcare.ahrq.gov/sites/default/files/related_files/recombinant-factor-viia_disposition-comments.pdf
   June 01, 2010 - Comparative Effectiveness of Recombinant Factor VIIa for Off-Label Indications vs. Usual Care. … Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. … Treatment of traumatic bleeding with recombinant factor VIIa. … Recombinant activated coagulation factor VII and bleeding trauma patients. … " or "Factor IX" or "Factor VIII" as if they were proper nouns, which they are not.

9. Refining Key Questions: Interactive Case Study Quiz
   effectivehealthcare.ahrq.gov/sites/default/files/related_files/rfviia.pptx
   May 01, 2010 - Introduction to Recombinant Activated Factor VII (rFVIIa) Yank V, et al. … Introduction to Recombinant Activated Factor VII (rFVIIa) Recombinant activated factor VII (rFVIIa) … X activation, even in the absence of tissue factor. … Recombinant factor VIIa for warfarin-associated intracranial bleeding. … Activated recombinant factor VII in orthotopic liver transplantation.

10. Refining Key Questions: Interactive Case Study Quiz
    effectivehealthcare.ahrq.gov/sites/default/files/rfviia.pptx
    May 01, 2010 - Introduction to Recombinant Activated Factor VII (rFVIIa) Yank V, et al. … Introduction to Recombinant Activated Factor VII (rFVIIa) Recombinant activated factor VII (rFVIIa) … X activation, even in the absence of tissue factor. … Recombinant factor VIIa for warfarin-associated intracranial bleeding. … Activated recombinant factor VII in orthotopic liver transplantation.

11. Data Points #15: Prognostic factor testing among older women with ductal carcinoma in situ and early invasive breast cancer | Effective Health Care Program
    effectivehealthcare.ahrq.gov/products/dcis-prognostic-tests
    September 13, 2012 - Data Points #15: Prognostic factor testing among older women with ductal carcinoma in situ and early … September 13, 2012 Research Report Data Points #15: Prognostic factor

12. Rapid Evidence Product: Adverse Events Associated With COVID-19 Pharmaceutical Treatments (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/COVID-19-pharmaceutical-treatments-rapid-review.pdf
    March 01, 2024 - RR = 0.98; CI: 0.06, 15.05 Neurosensory alteration: 0/40, 1/39 RR = 0.33; CI: 0.01, 7.95 Risk factor … units Titer: high titer Timing: 9 days Control: Placebo Cutoff: 45 days or less: 28 Risk factor … Analysis Risk of Bias (ROB) RR = 2.96; CI: 0.12, 72.49 Risk factor analysis: NR Pub … Analysis Risk of Bias (ROB) RR = 3.03; CI: 0.12, 74.27 Risk factor analysis: NR Pub … Analysis Risk of Bias (ROB) RR = 3.02; CI: 0.12, 73.90 Risk factor analysis: NR Pub

13. Effective Health Care (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND_0068_01-30-2009.pdf
    January 01, 2009 - Results of Topic Selection Process & Next Steps  Antinuclear autoantibody and rheumatoid factor … The nominator is interested in the diagnostic accuracy of antinuclear antibody (ANA) and rheumatoid factor … 3. a) What is the diagnostic accuracy of antinuclear antibody (ANA) and rheumatoid factor (RF) for children … vague musculoskeletal complaints  Age  Race/ethnicity Antinuclear Autoantibody and Rheumatoid Factor

14. Immune System and Disorders | Effective Health Care (EHC) Program
    effectivehealthcare.ahrq.gov/health-topics/immune-system-and-disorders
    July 16, 2013 - Research Protocol Archived January 20, 2012 Antinuclear Antibody, Rheumatoid Factor … Children Systematic Review Archived March 7, 2012 Antinuclear Antibody, Rheumatoid Factor

15. Community Forum Deliberative Methods Demonstration: Evaluating Effectiveness and Eliciting Public Views on Use of Evidence | Effective Health Care (EHC) Program
    effectivehealthcare.ahrq.gov/products/deliberative-methods/research-2013-1
    November 01, 2013 - Evidence of physical harm was the most persuasive factor in accepting boundaries. … Evidence of economic harm was also a persuasive factor in restricting choice. … After completing a factor analysis using the attitude items, our final attitude measures included six … Ratings for the factor assessing facilitator neutrality were fairly high. … For the implementation process, CD reported higher scores for the factor implementation quality.

16. Community Forum Deliberative Methods Demonstration: Evaluating Effectiveness and Eliciting Public Views on Use of Evidence--Executive Summary (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/deliberative-methods-demonstration-executive-131125.pdf
    November 01, 2013 - • Evidence of physical harm was the most persuasive factor in accepting boundaries. … • Evidence of economic harm was also a persuasive factor in restricting choice. … Ratings for the factor assessing facilitator neutrality were fairly high. … For the quality of communication and discourse, CD reported higher scores for the factor respect for … For the implementation process, CD reported higher scores for the factor implementation quality.

17. MEDLINE Searches (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/breast-cancer-medications_appendixes.pdf
    March 01, 2009 - Single risk factor only 102. Dignam JJ, Fisher B. … Effect of raloxifene on insulin-like growth factor-I, insulin-like growth factor binding protein-3, … Single risk factor only 230. Potter CE, Beldock JG. … Single risk factor only 237. Rhodes DJ. … Single risk factor only 273. Swerdlow AJ, Jones ME.

18. Antinuclear Antibody, Rheumatoid Factor, and Cyclic-Citrullinated Peptide Tests for Evaluating Musculoskeletal Complaints in Children | Effective Health Care (EHC) Program
    effectivehealthcare.ahrq.gov/products/musculoskeletal-complaints-tests-children/research
    March 07, 2012 - Disposition of Comments Report Jul. 3, 2013 Surveillance Report Antinuclear Antibody, Rheumatoid Factor … Structured Abstract Objectives To assess the test performance of antinuclear antibody (ANA), rheumatoid factor

19. Antinuclear Antibody, Rheumatoid Factor, and Cyclic-Citrullinated Peptide Testing for the Evaluation of Musculoskeletal Complaints in Pediatric Populations | Effective Health Care (EHC) Program
    effectivehealthcare.ahrq.gov/products/musculoskeletal-complaints-tests-children/research-protocol
    September 29, 2010 - Disposition of Comments Report Jul. 3, 2013 Surveillance Report Antinuclear Antibody, Rheumatoid Factor … The rheumatoid factor (RF) test is the most commonly used serological test to determine the presence … Rheumatoid factor and anti-CCP autoantibodies in rheumatoid arthritis: A review. … Rheumatoid factor test (RF): The measure of serum level of rheumatoid factor antibody which is an antibody … exp Rheumatoid Factor/ (rheumatoid adj factor*).ti,ab.

20. Data Points #15: Prognostic factor testing among older women with ductal carcinoma in situ and early invasive breast cancer | Effective Health Care (EHC) Program
    effectivehealthcare.ahrq.gov/products/dcis-prognostic-tests/research
    September 13, 2012 - Data Points #15: Prognostic factor testing among older women with ductal carcinoma in situ and early … Current guidelines do not recommend routine testing for human epidermal growth factor receptor 2 (HER2 … tissue is tested for estrogen receptors (ERs), progesterone receptors (PRs), and human epidermal growth factor